First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation
An abstract of the study of Kim et al. about BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation is presented. Among other things FGFR4 and its ligand, FGF19, normally promote hepatocyte proliferation and regulate bile acid ho...
Gespeichert in:
| Veröffentlicht in: | European journal of cancer (1990) 2016-12, Vol.69, p.S41-S41 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | S41 |
|---|---|
| container_issue | |
| container_start_page | S41 |
| container_title | European journal of cancer (1990) |
| container_volume | 69 |
| creator | Kim, R Sharma, S Meyer, T Sarker, D Macarulla, T Sung, M Choo, S.P Shi, H Schmidt-Kittler, O Clifford, C Wolf, B Llovet, J.M |
| description | An abstract of the study of Kim et al. about BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation is presented. Among other things FGFR4 and its ligand, FGF19, normally promote hepatocyte proliferation and regulate bile acid homeostasis; however, emerging data show FGF19 overexpression in up to 30% of HCC and implicate FGF19-dependent FGFR4 activation as a driver of hepatocarcinogenesis. A phase 1 study (NCT02508467) was initiated to assess the safety, PK, PD and preliminary clinical activity of BLU-554, a potent, highly-selective, oral FGFR4 inhibitor. BLU-554, a potent, highly-selective FGFR4 inhibitor has acceptable tolerability in pts with advanced HCC and demonstrates objective clinical activity in FGF19 IHC-positive disease. These data further implicate the FGFR4 pathway as a driver in HCC and provide the first proof of principle for targeting FGFR4 in HCC. Expanded clinical testing of BLU-554 with prospective selection of FGF19 IHC-positive HCC pts is underway. |
| doi_str_mv | 10.1016/S0959-8049(16)32704-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2037438883</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0959804916327046</els_id><sourcerecordid>2037438883</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1813-ea4bbb0ac6a5182d4678d95b8a6aeacd661a1a60554b0a3567f3c9bc786f0caa3</originalsourceid><addsrcrecordid>eNo9kVFLHDEQx0Op0Kv6EQqBvigYTTa72exLoR6eCgdCq89hNpt1Y_eSa5JV9oP0-zZ3Jz4NA7_5DTN_hL4xeskoE1e_aVM1RNKyOWPinBc1LYn4hBZM1g2hsio-o8UH8gV9jfGFUlrLki7Qv5UNMRHryDBtwOGYpm7GvsfX6ydSVeUFBrz1ybh0gQf7PIwziWY0OtlXg1e3q18ltm6wrU0-4M5E--xMh_vcDGYLyWszjtMIAWsI2jq_AXx2t1ye4zebhndB5oY3mDHsrJCsdyfoqIcxmtP3eoyeVjePyzuyfri9X_5cE80k48RA2bYtBS2gYrLoSlHLrqlaCQIM6E4IBgwEzXdkilei7rluWl1L0VMNwI_R94N3G_zfycSkXvwUXF6pCsrrkkspeaaqA6WDjzGYXm2D3UCYFaNql4DaJ6B271W52yegRJ77cZgz-YRXa4LSo3VWw_jHzCZ-rGIqFooeJDsHE3uD4P8BiDqOhw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2037438883</pqid></control><display><type>article</type><title>First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation</title><source>Elsevier ScienceDirect Journals</source><creator>Kim, R ; Sharma, S ; Meyer, T ; Sarker, D ; Macarulla, T ; Sung, M ; Choo, S.P ; Shi, H ; Schmidt-Kittler, O ; Clifford, C ; Wolf, B ; Llovet, J.M</creator><creatorcontrib>Kim, R ; Sharma, S ; Meyer, T ; Sarker, D ; Macarulla, T ; Sung, M ; Choo, S.P ; Shi, H ; Schmidt-Kittler, O ; Clifford, C ; Wolf, B ; Llovet, J.M</creatorcontrib><description>An abstract of the study of Kim et al. about BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation is presented. Among other things FGFR4 and its ligand, FGF19, normally promote hepatocyte proliferation and regulate bile acid homeostasis; however, emerging data show FGF19 overexpression in up to 30% of HCC and implicate FGF19-dependent FGFR4 activation as a driver of hepatocarcinogenesis. A phase 1 study (NCT02508467) was initiated to assess the safety, PK, PD and preliminary clinical activity of BLU-554, a potent, highly-selective, oral FGFR4 inhibitor. BLU-554, a potent, highly-selective FGFR4 inhibitor has acceptable tolerability in pts with advanced HCC and demonstrates objective clinical activity in FGF19 IHC-positive disease. These data further implicate the FGFR4 pathway as a driver in HCC and provide the first proof of principle for targeting FGFR4 in HCC. Expanded clinical testing of BLU-554 with prospective selection of FGF19 IHC-positive HCC pts is underway.</description><identifier>ISSN: 0959-8049</identifier><identifier>EISSN: 1879-0852</identifier><identifier>DOI: 10.1016/S0959-8049(16)32704-6</identifier><language>eng</language><publisher>Oxford: Elsevier Science Ltd</publisher><subject>Activation ; Fibroblast growth factor receptor 4 ; Hematology, Oncology and Palliative Medicine ; Hepatocellular carcinoma ; Homeostasis ; Inhibitors ; Liver cancer ; Studies ; Thyroid cancer</subject><ispartof>European journal of cancer (1990), 2016-12, Vol.69, p.S41-S41</ispartof><rights>Elsevier Ltd</rights><rights>Copyright Elsevier Science Ltd. Dec 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1813-ea4bbb0ac6a5182d4678d95b8a6aeacd661a1a60554b0a3567f3c9bc786f0caa3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Kim, R</creatorcontrib><creatorcontrib>Sharma, S</creatorcontrib><creatorcontrib>Meyer, T</creatorcontrib><creatorcontrib>Sarker, D</creatorcontrib><creatorcontrib>Macarulla, T</creatorcontrib><creatorcontrib>Sung, M</creatorcontrib><creatorcontrib>Choo, S.P</creatorcontrib><creatorcontrib>Shi, H</creatorcontrib><creatorcontrib>Schmidt-Kittler, O</creatorcontrib><creatorcontrib>Clifford, C</creatorcontrib><creatorcontrib>Wolf, B</creatorcontrib><creatorcontrib>Llovet, J.M</creatorcontrib><title>First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation</title><title>European journal of cancer (1990)</title><description>An abstract of the study of Kim et al. about BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation is presented. Among other things FGFR4 and its ligand, FGF19, normally promote hepatocyte proliferation and regulate bile acid homeostasis; however, emerging data show FGF19 overexpression in up to 30% of HCC and implicate FGF19-dependent FGFR4 activation as a driver of hepatocarcinogenesis. A phase 1 study (NCT02508467) was initiated to assess the safety, PK, PD and preliminary clinical activity of BLU-554, a potent, highly-selective, oral FGFR4 inhibitor. BLU-554, a potent, highly-selective FGFR4 inhibitor has acceptable tolerability in pts with advanced HCC and demonstrates objective clinical activity in FGF19 IHC-positive disease. These data further implicate the FGFR4 pathway as a driver in HCC and provide the first proof of principle for targeting FGFR4 in HCC. Expanded clinical testing of BLU-554 with prospective selection of FGF19 IHC-positive HCC pts is underway.</description><subject>Activation</subject><subject>Fibroblast growth factor receptor 4</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Hepatocellular carcinoma</subject><subject>Homeostasis</subject><subject>Inhibitors</subject><subject>Liver cancer</subject><subject>Studies</subject><subject>Thyroid cancer</subject><issn>0959-8049</issn><issn>1879-0852</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNo9kVFLHDEQx0Op0Kv6EQqBvigYTTa72exLoR6eCgdCq89hNpt1Y_eSa5JV9oP0-zZ3Jz4NA7_5DTN_hL4xeskoE1e_aVM1RNKyOWPinBc1LYn4hBZM1g2hsio-o8UH8gV9jfGFUlrLki7Qv5UNMRHryDBtwOGYpm7GvsfX6ydSVeUFBrz1ybh0gQf7PIwziWY0OtlXg1e3q18ltm6wrU0-4M5E--xMh_vcDGYLyWszjtMIAWsI2jq_AXx2t1ye4zebhndB5oY3mDHsrJCsdyfoqIcxmtP3eoyeVjePyzuyfri9X_5cE80k48RA2bYtBS2gYrLoSlHLrqlaCQIM6E4IBgwEzXdkilei7rluWl1L0VMNwI_R94N3G_zfycSkXvwUXF6pCsrrkkspeaaqA6WDjzGYXm2D3UCYFaNql4DaJ6B271W52yegRJ77cZgz-YRXa4LSo3VWw_jHzCZ-rGIqFooeJDsHE3uD4P8BiDqOhw</recordid><startdate>20161201</startdate><enddate>20161201</enddate><creator>Kim, R</creator><creator>Sharma, S</creator><creator>Meyer, T</creator><creator>Sarker, D</creator><creator>Macarulla, T</creator><creator>Sung, M</creator><creator>Choo, S.P</creator><creator>Shi, H</creator><creator>Schmidt-Kittler, O</creator><creator>Clifford, C</creator><creator>Wolf, B</creator><creator>Llovet, J.M</creator><general>Elsevier Science Ltd</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20161201</creationdate><title>First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation</title><author>Kim, R ; Sharma, S ; Meyer, T ; Sarker, D ; Macarulla, T ; Sung, M ; Choo, S.P ; Shi, H ; Schmidt-Kittler, O ; Clifford, C ; Wolf, B ; Llovet, J.M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1813-ea4bbb0ac6a5182d4678d95b8a6aeacd661a1a60554b0a3567f3c9bc786f0caa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Activation</topic><topic>Fibroblast growth factor receptor 4</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Hepatocellular carcinoma</topic><topic>Homeostasis</topic><topic>Inhibitors</topic><topic>Liver cancer</topic><topic>Studies</topic><topic>Thyroid cancer</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, R</creatorcontrib><creatorcontrib>Sharma, S</creatorcontrib><creatorcontrib>Meyer, T</creatorcontrib><creatorcontrib>Sarker, D</creatorcontrib><creatorcontrib>Macarulla, T</creatorcontrib><creatorcontrib>Sung, M</creatorcontrib><creatorcontrib>Choo, S.P</creatorcontrib><creatorcontrib>Shi, H</creatorcontrib><creatorcontrib>Schmidt-Kittler, O</creatorcontrib><creatorcontrib>Clifford, C</creatorcontrib><creatorcontrib>Wolf, B</creatorcontrib><creatorcontrib>Llovet, J.M</creatorcontrib><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>European journal of cancer (1990)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, R</au><au>Sharma, S</au><au>Meyer, T</au><au>Sarker, D</au><au>Macarulla, T</au><au>Sung, M</au><au>Choo, S.P</au><au>Shi, H</au><au>Schmidt-Kittler, O</au><au>Clifford, C</au><au>Wolf, B</au><au>Llovet, J.M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation</atitle><jtitle>European journal of cancer (1990)</jtitle><date>2016-12-01</date><risdate>2016</risdate><volume>69</volume><spage>S41</spage><epage>S41</epage><pages>S41-S41</pages><issn>0959-8049</issn><eissn>1879-0852</eissn><abstract>An abstract of the study of Kim et al. about BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation is presented. Among other things FGFR4 and its ligand, FGF19, normally promote hepatocyte proliferation and regulate bile acid homeostasis; however, emerging data show FGF19 overexpression in up to 30% of HCC and implicate FGF19-dependent FGFR4 activation as a driver of hepatocarcinogenesis. A phase 1 study (NCT02508467) was initiated to assess the safety, PK, PD and preliminary clinical activity of BLU-554, a potent, highly-selective, oral FGFR4 inhibitor. BLU-554, a potent, highly-selective FGFR4 inhibitor has acceptable tolerability in pts with advanced HCC and demonstrates objective clinical activity in FGF19 IHC-positive disease. These data further implicate the FGFR4 pathway as a driver in HCC and provide the first proof of principle for targeting FGFR4 in HCC. Expanded clinical testing of BLU-554 with prospective selection of FGF19 IHC-positive HCC pts is underway.</abstract><cop>Oxford</cop><pub>Elsevier Science Ltd</pub><doi>10.1016/S0959-8049(16)32704-6</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0959-8049 |
| ispartof | European journal of cancer (1990), 2016-12, Vol.69, p.S41-S41 |
| issn | 0959-8049 1879-0852 |
| language | eng |
| recordid | cdi_proquest_journals_2037438883 |
| source | Elsevier ScienceDirect Journals |
| subjects | Activation Fibroblast growth factor receptor 4 Hematology, Oncology and Palliative Medicine Hepatocellular carcinoma Homeostasis Inhibitors Liver cancer Studies Thyroid cancer |
| title | First-in-human study of BLU-554, a potent, highly-selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T12%3A23%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=First-in-human%20study%20of%20BLU-554,%20a%20potent,%20highly-selective%20FGFR4%20inhibitor%20designed%20for%20hepatocellular%20carcinoma%20(HCC)%20with%20FGFR4%20pathway%20activation&rft.jtitle=European%20journal%20of%20cancer%20(1990)&rft.au=Kim,%20R&rft.date=2016-12-01&rft.volume=69&rft.spage=S41&rft.epage=S41&rft.pages=S41-S41&rft.issn=0959-8049&rft.eissn=1879-0852&rft_id=info:doi/10.1016/S0959-8049(16)32704-6&rft_dat=%3Cproquest_cross%3E2037438883%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2037438883&rft_id=info:pmid/&rft_els_id=1_s2_0_S0959804916327046&rfr_iscdi=true |